Maureen R. Bleam

GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained <i>In Vivo</i> Pathway Inhibition

Aidan G. Gilmartin, Maureen R. Bleam, Arthur Groy et al. · Clinical Cancer Research · 2011 · 601 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13

Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by <i>NRAS</i> or <i>MEK</i> Mutations

James Greger, Stephen D. Eastman, Vivian Zhang et al. · Molecular Cancer Therapeutics · 2012 · 374 citations

Medicine, Oncology, Pharmacology +16

Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin Lesions

Alastair J. King, Marc R. Arnone, Maureen R. Bleam et al. · PLoS ONE · 2013 · 217 citations · Full text

Medicine, Oncology, Pharmacology +16

Distinct Concentration-Dependent Effects of the Polo-like Kinase 1–Specific Inhibitor GSK461364A, Including Differential Effect on Apoptosis

Aidan G. Gilmartin, Maureen R. Bleam, Mark C. Richter et al. · Cancer Research · 2009 · 133 citations · Full text

Life Sciences, Pharmacology, Apoptosis +13

Sensitivity of Cancer Cells to Plk1 Inhibitor GSK461364A Is Associated with Loss of p53 Function and Chromosome Instability

Yan Degenhardt, Joel Greshock, Sylvie Laquerre et al. · Molecular Cancer Therapeutics · 2010 · 91 citations

Life Sciences, Molecular Biology, Oncology +17